DC
BNTX icon

Davenport & Co’s BioNTech BNTX Stock Holding History

Davenport & Co’s Portfolio BNTX Stock Details BNTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-10,722
Closed -$862K – 1150
2024
Q2 		$862K Sell
10,722
-810
-7% -$74K 0.01% 652
2024
Q1 		$1.06M Buy
11,532
+126
+1% +$12.1K 0.01% 605
2023
Q4 		$1.2M Buy
+11,406
New +$1.15M 0.01% 538

Other funds holding BNTX

Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Flossbach Von Storch
Flossbach Von Storch Cologne, Germany $21.4B AUM 8.31% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
CII
Capital International Inc Los Angeles, California $13B AUM 31.88% 1-Year Est. Return
CS
Candriam SCA Strassen, Luxembourg, Luxembourg $19.3B AUM 39.18% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Davenport & Co's BNTX Position: Q3 2024 in Review

Davenport & Co sold out of BioNTech (BNTX) in Q3 2024, closing a stake of 10,722 shares — an estimated $862K sold.

Davenport & Co first reported a position in BNTX in Q4 2023 and held it in 3 quarters. The position peaked at $1.2M in Q4 2023. 296 funds tracked by Wall St. Rank hold BNTX as of Q3 2024.

  • Davenport & Co reported no remaining BioNTech position as of Q3 2024 after selling out during the quarter.
  • Davenport & Co sold 10,722 BioNTech shares in Q3 2024, an estimated $862K.
  • Davenport & Co first reported a position in BioNTech in Q4 2023 and held it in 3 quarters.
  • Davenport & Co's BioNTech position peaked at $1.2M in Q4 2023.
  • 296 funds tracked by Wall St. Rank held BioNTech as of Q3 2024.

Based on Davenport & Co's 13F filing for Q3 2024, filed 24 Oct 2024.